New Indication: Avelumab and Axitinib in Thymic Carcinoma


  • Study

    Single-arm, multicentre, phase 2 trial
    Had received at least one line of platinum-based chemotherapy
    Advanced stage thymoma or thymic carcinoma
    Avelumab 10 mg/kg/14 day and axitinib 5 mg x 2. (N:32)



  • Efficacy

    ORR: 34% (CR: 0, PR: 34%) and SD: 56%
    mPFS: 7.5 months
    DOR: 5.5 month



  • Safety

    Grade 1 or 2 infusion reactions: 9%
    Grade ≥3 AEs: Hypertension:19%, CK increase:9%
    Deaths due to adverse events: No



  • Lancet Oncol. 2022 Sep 9;S1470-2045(22)00542-3.

    Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

    http://doi.org/10.1016/s1470-2045(22)00542-3

    Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022